Chiron Seeking To Bump Up Buyout Bid? Directors Reject Novartis’ Offer
This article was originally published in The Pink Sheet Daily
Executive Summary
A $4.5 bil. cash offer from Novartis for an outstanding 57.8% stake in Chiron is “inadequate,” according to Chiron’s independent directors.You may also be interested in...
Second Time's The Charm: Novartis' New Bid Lures Chiron
Second Time's The Charm: Novartis' New Bid Lures Chiron
Novartis Willing To “Walk Away” From Chiron Bid
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: